News
April 4, 2025
To our valued customers,
In light of the April 2 announcement from U.S. President Donald Trump regarding new tariffs on U.S. global trading partners, we want to assure you that we are diligently analyzing the effect of these tariffs on our supply chain.
Elevaris Medical Devices manufacturers and sources its products primarily in South Korea and the United Kingdom. Like every other country in the world, these nations are subject to the new U.S. tariffs regime.
We appreciate your partnership as we collaboratively address this challenge. We look forward to working with you to minimize the tariffs’ impact to the extent possible and will have further updates soon.
Until then, kind regards,
Jason Pedaci
Chief Commercial Officer
Elevaris Medical Devices
Date: January 31, 2025
From: Jason Pedaci, Chief Commercial Officer
Subject: Additional Rebranding Information
We wanted to provide our customers more details on our adoption of the Elevaris brand and what it means for operations going forward. In approaching this process, we had a goal of rebranding with as little disruption to our customers as possible.
What is changing?
- Top Level Brand – When we talk about the company going forward, it will be as Elevaris, rather than Spectra or XL PT.
- Logo and Marketing - To the extent they have branding now, the logos on the marketing materials and labeling we provide will eventually be updated to the Elevaris brand. Marketing material content will discuss the company as a unified whole. Prior to changing the logo on any product labeling, we will engage with each customer to ensure a smooth transition process. Logo changes are the only expected changes to product labeling.
- Website and Emails – Over the next few months, our websites will merge and become elevarismedical.com and our email addresses will be updated; but don’t worry, anything sent to the old addresses will make it to us.
What is not changing?
- Manufacturer of Record – Both Spectra Medical Devices, LLC and XL PT Ltd. continue to exist as entities under the same names, continue to hold regulatory approvals as necessary and will continue to be listed as the manufacturers on their applicable product labeling. By design, this branding change should not require new quality agreements, significant regulatory filings, or other heavy QARA lifts.
- Product Quality and Characteristics – We will keep making the same great products we have in the past, no changes are anticipated in product specifications beyond logo updates to the extent applicable.
- Contracting Party - You will still contract with and be billed by the entities as they exist today – the logo on the invoices will change, but the corporate party remains the same. New contracts are not necessary.
- Tax IDs - No new W-9s are necessary, as the contracting entities and their Tax IDs remain the same.
Elevaris Medical Devices
Brand Day customer communication
Date: January 28, 2025
From: Jason Pedaci, Chief Commercial Officer
Subject: Spectra Medical Rebrand
I’m hoping you’ve already seen today’s announcement that Spectra Medical and XL Precision Technologies have rebranded as Elevaris Medical Devices. In the event that you haven’t, I’ve attached it to this note.
Our rebrand is another significant milestone in our journey together since Spectra acquired XLPT in September 2024. It’s our promise to leverage the strengths of our individual brands while emphasizing our singular commitment to you.
Our new brand is our pledge to unparalleled customer collaboration. It marks our dedication to the knowledge, solutions orientation, and precision manufacturing capabilities you trust. And It’s our promise to provide a level of attentiveness and responsiveness that other device engineers and manufacturers can’t or won’t.
As Elevaris Medical Devices, we’re excited to produce the devices and components you already know providers need. And we look forward to helping you design, develop, and manufacture the next-generation medical devices you imagine. From inception to commercialization, Elevaris Medical Devices
will be focused intently on your goals and committed to elevating your outcomes to the next level.
We’re honoring a legacy of trust and expertise and look forward to working together to deliver excellence. We’re excited to usher in a new era of precision medical device development and manufacturing capabilities, and we’re honored to share it with you.
Be sure to reach out if you have questions. I look forward to connecting.
Spectra Medical, XL Precision Technologies Announce Rebrand as Elevaris Medical Devices
Legacy of Trust and Expertise Ushers in New Era of Precision Medical Device Development and Manufacturing Capabilities
Boston — Jan. 28, 2025 — Spectra Medical Devices (Spectra) and XL Precision Technologies (XLPT) announced today their newly combined brand presence as Elevaris Medical Devices, a world-class Contract Development and Manufacturing Organization (CDMO) leveraging a proven legacy of excellence to usher in a new era of precision medical device development and manufacturing capabilities.
The Spectra acquisition of XLPT, announced in September 2024 by healthcare technology and services investor QHP Capital, brought together the companies’ complementary strengths in servicing medical device manufacturers from large-scale Original Equipment Manufacturers (OEMs) to startups. Spectra has long been highly regarded for the expansive engineering and manufacturing capabilities and expert technical customer support it provides OEMs. XLPT is widely admired for its specialty manufacturing expertise in precision micro-components, complex tubular components, and sub-assemblies.
Today’s announcement marks the formal evolution to a unified brand that equally honors the rich history of each company and embodies their combined commitment to providing their deep knowledge, unparalleled collaborative approach, and extensive precision manufacturing capabilities to customers worldwide. The decision to establish a new company name and brand identity reflects the promise to apply the best practices and strengths of the individual brands while also emphasizing a singular commitment to elevating customer outcomes to the next level.
“The acquisition late last year brought together two long-trusted companies with highly complementary capabilities,” Richard Zrebiec, CEO of Elevaris Medical Devices, said. “Today, as we complete integration, we believe operating under one brand demonstrates our combined commitment to our customers’ success.”
As the newly branded company, Elevaris Medical Devices will serve medical device companies in an unrivaled capacity. The unified team of engineering, design, and development experts is highly invested in applying its deep knowledge and product perspective to provide value-driven design, development and production solutions that support the success of customer projects.
“From concept, to design and development, through manufacturing, we are uniquely qualified to support our customers in their quest to develop next-generation medical devices that enable the future of healthcare and improve global health,” Zrebiec said. “Elevaris Medical Devices has the capability to be the preferred partner to drive a new era of precision medical device development and manufacturing.”
About Elevaris Medical Devices:
Elevaris Medical Devices is a Contract Development and Manufacturing Organization (CDMO) for industry-leading, multi-national healthcare companies, global Original Equipment Manufacturers (OEMs), and emerging technology companies. It is one of the world's leading manufacturers of made-to-spec procedural needles and specializes in the manufacture of precision micro-components, complex tubular components, and sub-assemblies for the medical device industry. The company also distributes a wide range of complementary pharmaceutical products, surgical instruments, and medical supplies.
Elevaris Medical Devices has more than 300 employees across its locations in North America, the UK, and South Korea. For more information, visit elevarismedical.com.
Spectra Medical Devices Acquires XL Precision Technologies
September 30, 2024
Wilmington, MA & Stockton-on-Tees, UK – Spectra Medical Devices, LLC (“Spectra”), a
portfolio company of QHP Capital, is pleased to announce the closing of its acquisition of XL
Precision Technologies Ltd. (“XL-PT”). XL-PT is now a wholly-owned subsidiary of Spectra.
XL-PT is a Contract Development and Manufacturing Organization (“CDMO”) specializing in the
manufacture of precision micro-components, complex tubular components, and sub-assemblies
for the medical device industry. XL-PT has a track record of developing and manufacturing
complex componentry for their customers with speed and precision.
The acquisition brings together companies with complementary strengths, enhancing Spectra’s
ability to serve industry-leading medical device original equipment manufacturers (“OEMs”).
The combined development and manufacturing capabilities are expected to generate
significant growth over the coming years and further solidify Spectra’s position as a CDMO
partner of choice.
“We are thrilled to announce Spectra’s acquisition of XL-PT. This acquisition expands and
enhances our development and manufacturing capabilities allowing us to do more for our
customers and the medical device community,” said Chad Nikel, CEO of Spectra. “By combining
the commercial reach, procedural needle manufacturing expertise, and scale of Spectra with
XL-PT’s robust development services and precision manufacturing capabilities, we are equipped
to deliver even greater value to customers and meet a broader set of customer needs.”
“The combination of XL-PT and Spectra brings together highly complementary capabilities:
Spectra’s reputation for quality and blue-chip customer base and XL-PT’s exceptional
engineering platform and advanced manufacturing techniques. We are excited to join forces
with Spectra. This creates a CDMO ideally positioned to serve medical device emerging
innovators and OEMs” added Tom Graham, Managing Director of XL-PT.
Rubicon Partners Industries, who acquired XL-PT in 2008, were the sellers. White & Case served
as legal advisor to Spectra. Piper Sandler served as financial advisor and Proskauer Rose served
as legal advisor to Rubicon Partners Industries.
About Spectra Medical Devices:
Spectra Medical Devices is one of the world's leading manufacturers of made-to-spec
procedural needles. Spectra is a CDMO to industry-leading, multi-national healthcare
companies, global OEMs, and emerging technology companies. Spectra also distributes a wide
range of complementary pharmaceutical products, surgical instruments, and medical supplies.
For more information, please visit www.spectramedical.com.
About XL Precision Technologies:
XL Precision Technologies is a CDMO specializing in the manufacture of precision microcomponents, complex tubular components, and sub-assemblies for the medical device industry. XL-PT utilizes laser, electrical discharge machining (EDM), and other advanced manufacturing
technologies to serve a wide range of medical applications, including cardio- and neurovascular,
endoscopy and laparoscopy, sports medicine, ophthalmology and drug delivery. XL-PT also
offers tailored development services such as quick-turn prototyping and technical support to
meet the needs of medical device customers during new product development. For more
information, please visit www.xlprecisiontechnologies.com.
About QHP Capital:
QHP Capital is an investor in technology and services companies in the life sciences, medical
technology, and healthcare sectors. QHP has built an investment platform to provide strategic
capital and industry expertise in partnership with strong management teams. The investment
team consists of seasoned investment and operational professionals with significant investment
experience and deep life science, medical technology, and healthcare expertise. QHP benefits
from an extensive network of industry experts that assist in identifying, analyzing, and growing
QHP’s portfolio companies. For more information, please visit www.qhpcapital.com.
Contacts:
Spectra Medical Devices
Chad Nickel
[email protected]
Readiness Opens Vast European Distribution Opportunities
March 22, 2024
Spectra Medical Devices, a global manufacturer of made-to-spec procedural needles and a distributor of complementary medical instruments, supplies, and pharmaceuticals, today announced that it has secured European Union Medical Device Regulation (EU MDR) certification for its entire range of radiofrequency (RF) needles.
The new EU MDR CE marking recognizes Spectra’s commitment to quality and exacting standards. The EU MDR includes product-specific requirements that exceed ISO 13485 organizational standards for medical device manufacturers to ensure the safety, performance, and quality of medical devices in the European market. With the CE marking, Spectra is now able to sell and distribute products in the European market.
“We are fiercely dedicated to quality standards, and we are proud to have received this recognition of our commitment to clinical safety and impeccable product performance,” said Chad Nikel, President and CEO of Spectra Medical Devices. “We’ve long been recognized for our precision procedural needles, and we are thrilled to be able to introduce them to the European market.”